RELB anticorps (C-Term) (Cy3)

N° du produit ABIN8053149

L’anticorps anti-RELB Polyclonal Lapin est utilisé pour la détection de RELB dans des échantillons de Humain, Souris et Rat. Il a été validé pour FACS.

Aperçu rapide pour RELB anticorps (C-Term) (Cy3) (ABIN8053149)

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RELB est conjugé à/à la Cy3

Application: Flow Cytometry (FACS)

Détail du produit anti-RELB anticorps (Cy3)

Épitope: C-Term

Fonction: Anti-Rel B/RELB Antibody Cy3 Conjugated

Specificité: No cross reactivity with other proteins.

Réactivité croisée (Details): No cross-reactivity with other proteins

Homologie: identical to the related mouse sequence.

Purification: Immunogen affinity purified.

Immunogène: A synthetic peptide corresponding to a sequence at the C-terminus of human Rel B, identical to the related mouse sequence.

Isotype: IgG

Information d'application

Indications d'application: Flow Cytometry, 1-3 μg/1x10⁶ cells

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: At -20°C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

Date de péremption: 12 months

Détails sur RELB

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Autre désignation: RELB

Sujet:

Background: RELB (v-rel reticuloendotheliosis viral oncogene homolog B) is also known as IREL. The International Radiation Hybrid Mapping Consortium assigned the RELB gene to chromosome 19. By RT-PCR and immunocytochemical analyses, Clark et al. (1999) showed that RELB expression correlated with dendritic cell activation. NF-kappa-B-inducing kinase is required for osteoclastogenesis in response to pathologic stimuli. Vaira et al. (2008) found that overexpression of Relb, but not Rela, rescued differentiation of mouse Nik -/- osteoclast precursors, indicating that blockade of the alternative NF-kappa-B pathway, rather than the classical NF-kappa-B pathway, is responsible for the osteoclastogenic defect in the absence of Nik. Using Relb -/- mice, they showed that Relb itself was required for Rankl-induced osteoclastogenesis in vitro and for TNF-induced bone resorption in vivo. Both Relb -/- and Nik -/- mice were resistant to tumor-mediated osteolysis. Vaira et al. (2008) concluded that the alternative NF-kappa-B pathway, via RELB, plays an essential and unique role in RANKL signaling toward osteoclast development.

Gene Full Name: RELB proto-oncogene, NF-kB subunit

Sequence Similarities: Contains 1 RHD (Rel-like) domain.

ID gène: 5971

UniProt: Q01201

Pathways: Signalisation NF-kappaB, Signalisation RTK